Which drug first? study seeks best order for neuroendocrine tumor therapy
NCT ID NCT07534371
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 500 people with advanced neuroendocrine tumors to see if starting with surufatinib or somatostatin analogs leads to better outcomes. Researchers will compare how long the cancer is controlled with each sequence. The goal is to provide real-world evidence to guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib and somatostatin analogs (octreotide or lanreotide)
What this could lead to
If successful, this study could identify the best order of treatments for advanced neuroendocrine tumors, helping doctors personalize care and potentially extend the time patients live without their cancer growing.
What could go wrong
This is a retrospective study, meaning it looks back at past data, not a controlled experiment. Results may be influenced by factors like patient selection or incomplete records, so they cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China